Many individuals using weight-loss medications such as Mounjaro, Wegovy, and Ozempic could unknowingly invalidate their travel and health insurance, according to new findings. A survey revealed that a significant portion of the public is unclear about how these medications should be classified when purchasing insurance.
Key Findings from the Survey:
Over 25% of UK adults were unsure whether weight-loss jabs like Mounjaro, Wegovy, and Ozempic should be disclosed as a pre-existing medical condition when purchasing travel insurance.
11% classified them as cosmetic treatments for appearance.
10% considered them lifestyle tools.
24% saw them as medical treatments.
The confusion stems from the fact that many insurance providers require the disclosure of pre-existing conditions. Failing to correctly report such information can lead to insurance claims being voided.
Ian Hughes, CEO of Consumer Intelligence, warned about the significant consequences of this confusion, stating, “This isn’t just an academic issue; it can result in real financial consequences for millions of Brits when purchasing travel and health insurance.”
The Financial Ombudsman Service reported a 19% increase in travel insurance complaints in 2024, with medical disclosure disputes being a primary cause of the rise in complaints.
Hughes emphasized the importance of clear communication between insurers and their customers. “When a quarter of the population is unsure about whether their medication counts as a pre-existing condition, this creates a perfect storm for claim disputes and coverage gaps,” he said.
Related topics:
